Milk fat globule-epidermal growth factor-factor 8 (MFG-E8) plays an immunomodulatory role in inflammatory diseases. MFG-E8-derived short peptide (MSP68) greatly reduces neutrophil infiltration and injury in the lung during sepsis. In this study, we examined the effect of MSP68 on chemotaxis of various immune cells and its regulatory mechanism. Bone marrow-derived neutrophils (BMDNs) from C57BL/6 mice, human monocyte THP-1 cell line, and human T lymphocyte Jurkat cell line were used for adhesion and migration assays using a Transwell method in the presence of MSP68. Treatment with MSP68 significantly inhibited the BMDN and THP-1 cell but not Jurkat cell adhesion on the TNF-a-stimulated pulmonary artery endothelial cell (PAEC) monolayer dose-dependently. MSP68 also significantly reduced BMDN adhesion on VCAM-1-coated wells dose dependently. Surface plasmon resonance (SPR) analysis revealed that MSP68 efficiently recognized integrin a 4 b 1 (receptor for VCAM-1) at the dissociation constant (K D ) of 1.53 3 10 27 M. These findings implicate that MSP68 prevents neutrophil adhesion to the activated endothelial cells by interfering with the binding between integrin a 4 b 1 on neutrophils and VCAM-1 on endothelial cells. Moreover, MSP68 significantly attenuated the migration of BMDN and THP-1 cells but not Jurkat cells to their chemoattractants. Pretreatment with MSP68 inhibited the transmigration of BMDNs across the PAECs toward chemoattractants, fMLP, MIP-2, and complement fragment 5a (C5a) dose-dependently. Finally, we identified that the activation of p38 MAPK in BMDNs by fMLP was inhibited by MSP68. Thus, MSP68 attenuates extravasation of immune cells through the endothelial cell lining into inflamed tissue, implicating MSP68 to be a novel, therapeutic agent for inflammatory diseases caused by excessive immune cell infiltration.
Introduction
Sepsis refers to severe systemic and local tissue inflammation caused by infection and is considered as the leading cause of death in noncoronary intensive care units [1, 2] . Infiltration of neutrophils and macrophages into the lung is implicated in the pathogenesis of sepsis-induced ALI [3, 4] . Although neutrophils play a crucial role in host defense against pathogens through the release of anti-bacterial proteins, formation of neutrophil extracellular traps, and phagocytosis [5] [6] [7] [8] [9] , patients with a low number of neutrophils in their circulation are susceptible to infection [10] . However, overwhelming infiltration of neutrophils, followed by excessive release of lytic factors in lungs, promotes unrestrained inflammation and damage to the capillary endothelium and alveolar epithelium, which in turn, may lead to the accumulation of protein-rich edema fluid, hemorrhage, and inactivation of surfactant in the lung during sepsis [11] [12] [13] . Macrophages that reside in the airways, alveoli, and interstitium or migrate into the lung during inflammation are capable of phagocytosing bacteria and apoptotic cells. Conversely, the macrophages are the source of cytokines and chemokines to induce neutrophil accumulation and inflammation into the lung [14, 15] . Hence, the regulation of leukocyte infiltration into the lung could be an effective therapeutic strategy in sepsis.
Mouse MFG-E8 is a 66 kDa secreted glycoprotein that is expressed in nearly all organs and various cell types, including macrophages, dendritic cells, and epithelial cells [16] . It is strongly expressed in mammary glands during lactation, as well as in the spleen, lungs, and liver [16] . MFG-E8 has been widely known to be protective against several inflammatory diseases, including sepsis and ischemia-reperfusion injury [17, 18] .
MFG-E8-mediated inhibition of neutrophil infiltration into the lungs has recently been reported, which led to protection against ALI [19] . To identify a specific domain of MFG-E8 responsible for the inhibition of neutrophil migration, we focused on the region flanking RGD motif that recognizes a v b 3 -integrin to promote cellular functions [20] .
MSP68 is a 5-aa containing a small peptide originally derived from its parent molecule MFG-E8 [20] . The peptide sequence of MSP68, which is derived from the parent MFG-E8 molecule, is highly conserved, as MFG-E8 contains the RGD motif in its structure. Previously, we reported the beneficial effect of MSP68 administration into the septic animal, which dramatically reduced neutrophil infiltration into the lungs and improved survival [20] .
After mobilization from the bone marrow during acute inflammation, circulating neutrophils infiltrate from the bloodstream into the inflamed extravascular tissue through multiple processes that involve a complex interaction between the neutrophil and the adjacent vascular endothelium [21] . For the initial step, neutrophils are captured and roll along microvascular walls by low-affinity interactions with 3 endothelial cell-surface transmembrane glycoproteins, termed E-, L-, and P-selectin. At the same time, chemotactic factors induced by proinflammatory cytokines activate neutrophil integrins that result in the subsequent high-affinity binding of neutrophils to the adhesive molecules, such as ICAM-1 and VCAM-1, expressed on activated endothelial cells. Finally, neutrophils transmigrate into the inflamed tissue from the vascular lumen by passing between (paracellular) or through (transcellular) the endothelial cells [21] .
With the consideration that neutrophil and other immune cell infiltration into the inflamed tissues involve several sequential steps of adhesion and migration from the vascular endothelial linings, we hypothesized that MSP68 has a direct effect on neutrophil and other immune cell adhesion and/or migration across the endothelial cells in the inflammatory condition. Hence, the current study was designed based on several in vitro experiments to delineate the mechanism of MSP68-mediated inhibition of neutrophil and other leukocyte infiltrations into the tissues during inflammation.
MATERIALS AND METHODS

Isolation of mouse BMDNs
Eight-week-old male C57BL/6 mice were purchased from Taconic Biosciences (Albany, NY, USA). Mouse operations were performed in accordance with the guidelines for the use of experimental animals by the U.S. National Institutes of Health (Bethesda, MD, USA), and the protocol was approved by the Institutional Animal Care and Use Committee at The Feinstein Institute for Medical Research. BMDNs were isolated as previously described [19] . In brief, mice were euthanized, and femurs from both hind legs were removed to collect bone marrow cells. A PBS-diluted Percoll (Sigma-Aldrich, St. Louis, MO, USA) gradient with 78, 69, and 52% layers was created, and the bone marrow-derived crude cell pellet was resuspended in Ca 2+ -and Mg 2+ -free HBSS and over-layered onto this gradient. The Percoll gradient was centrifuged for 30 min at 1300 g. A white layer formed between 78 and 69% Percoll gradients, mainly containing the granulocyte populations, was then collected and treated with ammonium-chloride-potassium lysing reagent (Quality Biological, Gaithersburg, MD, USA) for 5 min to remove RBCs and then washed by suspension in HBSS without Ca 2+ and Mg 2+ and centrifuged at 100 g for 10 min, finally to obtain the pure neutrophil pellet. Isolated BMDNs were resuspended in RPMI medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FBS, glutamine, penicillin, and streptomycin.
Flow cytometry
To assess the purity of BMDNs, isolated bone marrow cells were stained with antibodies allophycocyanin-Ly6G and PE-CD11b (BioLegend, San Diego, CA, USA). After washing, the stained cells were subjected to flow cytometric analysis by BD LSR Fortessa (BD Biosciences, San Jose, CA, USA 
Cell culture
Human primary PAECs were purchased from ATCC (Manassas, VA, USA) and cultured in complete PAEC growth medium with endothelial cell growth kit (ATCC). PAECs were subcultured when they reached ;80% of confluence. Passage 2-5 cells were used for all experiments. A human peripheral blood monocyte THP-1 cell line was purchased from ATCC and cultured in RPMI medium with 2-ME to a final concentration of 0.05 mM and with 10% FBS [22] . A human peripheral blood T lymphocyte Jurkat cell line, obtained from ATCC, was cultured in RPMI, supplemented with 10% FBS.
Adhesion assay
A 96-well plate was coated with 10 mg/ml recombinant mouse ICAM-1 or recombinant mouse VCAM-1 (R&D Systems, Minneapolis, MN, USA) at room temperature overnight. Another 96-well plate was seeded with PAECs and grown overnight, followed by stimulation with 10 nM TNF-a for 6 h. BMDNs were labeled with calcein-AM (Thermo Fisher Scientific) for 30 min and stimulated with 10 nM fMLP for 15 min. Then, the BMDNs were added to the 96-well plates coated with ICAM-1, VCAM-1, or activated PAECs in the presence or absence of MSP68 (synthesized by GenScript USA, Piscataway, NJ, USA). After incubation for 2 h, OD, at wavelengths of 485/538 nm, was recorded before washing the plate and after 23 PBS washing. The percentage of the adherent cells was calculated by the ratios of the ODs taken after and before washing. For the assessment of THP-1 cell adhesion, a total of 1 3 10 6 THP-1 cells were stimulated with 10 nM MCP-1 for 15 min and then were labeled with fluorescence dye calcein-AM. The labeled THP-1 cells were then added into a PAEC-monolayered plate. The PAECs were preactivated with 10 nM TNF-a for 6 h. THP-1 cells were allowed to adhere to the PAEC monolayer for 2 h in the presence of the indicated dose of MSP68 or PBS. Adhesion was quantified with a multiwell fluorescent spectrophotometer as absorbance (after 23 washing)/absorbance (prewash).
Real-time qRT-PCR
Total RNA was extracted from PAECs by using TRIzol (Thermo Fisher Scientific) and reverse transcribed into cDNA using RT (Thermo Fisher Scientific). A PCR was carried out in 25 ml final volume containing 0.1 mM each forward and reverse primer, cDNA, and 12.5 ml SYBR Green PCR Master Mix (Thermo Fisher Scientific). Amplification was conducted using a 7300 real-time PCR machine (Thermo Fisher Scientific) under the thermal profile of 50°C for 2 min, 95°C for 10 min, followed by 45 
SPR analysis
Binding kinetics of MSP68 with integrins was assessed by SPR analysis using the Biacore T200 instrument (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Binding reactions were performed in 13 PBS buffer containing 0. 
Migration assay
The migration assays were performed in a modified, 24-well (3.0 mm pore) Boyden chamber (BD Biosciences). BMDNs were stimulated by 10 nM fMLP for 15 min and then incubated with MSP68 for another 30 min. After washing with PBS, a total of 1 3 10 5 BMDNs were plated in the upper well, and C5a, fMLP, or MIP-2 at 10 nM was placed in the lower well as a chemotactic stimulus. After 2 h, the upper surface of the filter was swabbed with cotton to remove nonmigratory cells. Migrated cells were fixed with 10% formalin and stained with PI. Cell numbers were counted in 5 random fluorescence microscopic fields per well.
Transmigration assay
A total of 1 3 10 4 PAECs were seeded into the upper well of a 24-well Boyden chamber until confluent, followed by incubation with 10 nM TNF-a for 6 h. BMDNs were labeled with CFSE (Thermo Fisher Scientific) for 30 min and washed with PBS. The labeled cells were stimulated with 10 nM fMLP for 15 min and then incubated with MSP68 for another 30 min. After the wash with PBS, a total of 1.5 3 10 5 BMDNs were plated in the upper well grown with activated PAECs and subjected to migration assay, as described early.
Western blot analysis
BMDNs were homogenized in lysis buffer (10 mM Tris-HCl at pH 7.5, 120 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Protein concentration was determined by Bio-Rad protein assay reagent. Total lysates were fractionated on Bis-Tris gels (4-12%) and transferred to nitrocellulose membrane, which were then blocked with 5% nonfat dry milk in TBST and incubated overnight at 4°C with the primary antibodies, as obtained from respective vendors: anti-p-p38 MAPK (Thr180/Tyr182) and anti-p38 MAPK antibodies (Cell Signaling Technology, Beverly, MA, USA) and anti-b-actin antibody (Sigma-Aldrich). After the wash, the membranes were incubated with fluorescence-labeled secondary antibodies and scanned by the Odyssey imaging system (LI-COR Biosciences, Lincoln, NE, USA). To examine the expression of integrin a 4 , proteins extracted from a total of 2 3 10 6 cells of each of the BMDN, THP-1, and Jurkat cells were subjected to Western blot analysis using anti-a 4 integrin antibody (Cell Signaling Technology). The blot was stripped off and reprobed with the anti-b-actin antibody to show equal loading of the samples.
Statistical analysis
Data are expressed as means 6 SEM and analyzed using SigmaPlot 11 graphing and statistical analysis software (Systat Software, San Jose, CA, USA). Multiple groups were compared with 1-way ANOVA using the Student-Newman-Keuls test. Student's t test was used for 2-group analysis. Differences in values were considered significant if P , 0.05.
RESULTS
MSP68 inhibits BMDN adhesion on TNF-a-activated PAECs in a dose-dependent manner
The adhesion assay of activated BMDNs on PAECs was performed to assess the effect of MSP68 on neutrophil adhesion. Compared with the PBS-treated group, the treatment with MSP68 had no significant effect on BMDN adhesion to PAECs without TNF-a stimulation (Fig. 1A) . On the other hand, MSP68 treatment significantly reduced BMDN adhesion to TNF-a-activated PAECs by 36, 46 , and 50% at doses of 1, 10, and 50 nM, respectively, compared with the PBS-treated group (Fig. 1B) .
MSP68 inhibits BMDN adhesion on endothelial cell adhesion molecules
The cell adhesion molecules, such as ICAM-1 and VCAM-1, on endothelial cells are needed for the firm adhesion of neutrophils to endothelial cells during inflammation [23] . Therefore, we Figure 1 . MSP68 inhibits BMDN adhesion on TNF-a-activated PAECs in a dose-dependent manner. BMDNs stimulated with 10 nM fMLP for 15 min were labeled with fluorescence dye calcein-AM and added into a PAEC-coated plate. Before the coating, PAECs were (A) not activated (PBS treated) or (B) activated with 10 nM TNF-a for 6 h. BMDNs were allowed to adhere to PAECs for 2 h in the presence of the indicated dose of MSP68 or PBS. Adhesion was quantified with a multiwell fluorescent spectrophotometer as absorbance (after 23 washing)/ absorbance (prewash). The mean value of the PBS-treated control group was standardized at 100%. This was done by first dividing the uncorrected mean of the PBS-treated control group by 100 to obtain a multiplication factor. Every sample's value was then multiplied by this factor, resulting in a standardized mean of 100% for the control group and relative means for each treated group. *P , 0.05 vs. fMLP2; #P , 0.05 vs. fMLP+.
measured the gene-expression levels of ICAM-1 and VCAM-1 in PAECs after stimulation with the proinflammatory cytokine TNF-a. Compared with PBS-treated PAECs, the mRNA levels of ICAM-1 were significantly up-regulated by 5-fold in TNFa-treated PAECs ( Fig. 2A) . Likewise, the TNF-a stimulation also significantly increased the gene expression of VCAM-1 in PAECs by 29-fold compared with the PBS-treated PAECs (Fig. 2B ).
To determine further whether MSP68's inhibition of neutrophil adhesion to endothelial cells was mediated by the interaction with ICAM-1 and VCAM-1, we performed a BMDN adhesion assay to ICAM-1-and VCAM-1-coated plates. Compared with the PBS-treated group, at doses 1 and 10 nM of MSP68 treatment, although we did not notice statistically significant inhibition of BMDN adhesion to the ICAM-1-coated plates, at a higher dose of MSP68 (50 nM) stimulation, the BMDNs showed significant inhibition of their adhesion to the ICAM-1-coated plates by 34% (Fig. 2C) . On the other hand, the BMDNs treated with MSP68 showed a significant inhibition of their adhesion to VCAM-1-coated plates by 41, 68, and 70% at doses of 1, 10, and 50 nM, respectively, compared with the PBS-treated group (Fig. 2D ).
MSP68 directly binds to integrins
The RGD domain is known to bind to several integrins expressed on the neutrophil cell surface [24] . Therefore, we examined whether there was a direct binding of MSP68 to integrins a M b 2 (Mac-1) and a 4 b 1 (VLA-4), which are binding partners of ICAM-1 and VCAM-1, respectively [9] . By performing SPR analysis, we obtained the binding-affinity K D (molar) of MSP68 to Mac-1 and VLA-4 with 6.59 3 10 26 and 1.53 3 10
27
, respectively (Fig. 3) . In this kinetic study, various concentrations of MSP68 were added to show a dose-dependent interaction between these two molecules and further determined the K D values of MSP68 binding to Mac-1 and VLA-4. As the K D of MSP68 and VLA-4 interaction is lower than Mac-1 (i.e., high affinity), it can explain the better inhibition efficacy of MSP68 on VCAM-1 as shown in Fig. 2D . With the K D in the micromolar range, these results indicate that MSP68 has a direct physical interaction with these 2 integrins. 
MSP68 reduces BMDN migration toward chemoattractants in a dose-dependent manner
To examine the effect of MSP68 on neutrophil migration, we performed a Boyden chamber cell migration assay. The migrated cells toward each chemoattractant were fixed with formalin and stained with PI. Pretreatment of BMDNs with MSP68 at doses of 1, 10, and 50 nM inhibited their migration toward C5a by 34, 80, and 87%, respectively, compared with the PBS-treated BMDNs (Fig. 4A and B) . Likewise, MSP68 treatment at doses of 1, 10, and 50 nM significantly reduced the BMDN migration by 32, 53, and 88%, respectively, toward fMLP ( Fig. 4A and C) , as well as by 53, 70, and 79%, respectively, toward MIP-2 ( Fig. 4A and D) . Collectively, these data clearly revealed that the MSP68 treatment reduced BMDN migration toward several chemoattractants in a dose-dependent manner.
MSP68 reduces BMDN transmigration across PAECs
For extravasations into the lung tissues, neutrophils need to undergo transmigration across the endothelial layers in blood vessels. To mimic in vivo conditions, we examined the effect of MSP68 on CFSE-labeled BMDN transmigration through the PAEC monolayer by a Boyden chamber cell migration assay. As shown in Fig. 5A -D, BMDNs effectively transmigrated through activated PAECs toward C5a, fMLP, and MIP-2. However, pretreatment with MSP68 at a dose of 10 nM significantly reduced BMDN transmigration toward C5a by 48% compared with the PBS-treated BMDNs (Fig. 5A and B) . Likewise, MSP68 significantly inhibited the BMDN transmigration by 58% toward fMLP (Fig. 5A and C) and by 78% toward MIP-2 ( Fig.  5A and D) . 
MSP68 inhibits THP-1 adhesion to activated endothelial cells and chemotaxis to MCP-1
To assess the effect of MSP68 on THP-1 cell adhesion to the activated endothelial cells, THP-1 cells were pretreated with MSP68 at various concentrations, followed by the assessment of their adhesion to PAECs. Compared with the PBS-treated group, treatment with MSP68 at doses of 1 nM had no significant effect on THP-1 cell adhesion to PAECs, whereas the THP-1 cells treated with a high dose of MSP68 (50 nM) were able to show a significant inhibition of their adhesion to PAECs by 26% (Fig.  6A) . Furthermore, the effect of MSP68 on THP-1 cell migration to MCP-1 (CCL2) was performed in a Boyden chamber cell migration assay. MCP-1 is one of the key chemokines that promotes migration and infiltration of monocytes/macrophages [25] . Pretreatment of THP-1 cells with MSP68 at a dose of 50 nM significantly inhibited their migration toward MCP-1 by 69% compared with the PBS-treated THP-1 cells (Fig. 6B and C) . We also conducted a Jurkat cell adhesion assay to activated PAECs in the presence of MSP68. However, there was no change in the adhesion of Jurkat cells pretreated with MSP68 at 50 nM (data not shown).
Differential expression of integrin a 4 in BMDNs, THP-1, and Jurkat cells
With the consideration of integrin a 4 as one of the receptors for MSP68, we aimed to assess the status of integrin a 4 expression in BMDNs, THP-1, and Jurkat cells by Western blotting. As shown in Fig. 7A and B, the expressions of integrin a 4 in THP-1 and Jurkat cells was significantly higher than the BMDNs, whereas the expression of integrin a 4 in Jurkat cells was even found to be more significantly higher than that of THP-1 cells.
MSP68 down-regulates p-p38 in BMDN
It has been reported that activation of p38, a MAPK, is involved in the regulation of neutrophil migration toward chemoattractants [20, 24] . Therefore, we measured the activation status of p38 in terms of p-p38 in fMLP-stimulated BMDNs by Western blotting in the absence or presence of MSP68. As shown in Fig. 8, p38 was activated in BMDNs and reached a 1.8-fold increase in its phosphorylation level at 60 min after stimulation with fMLP compared with the time 0 control. MSP68 treatment reduced fMLP-triggered p-p38 in BMDNs by 29, 50, 11, and 20% at 10, 30, 60, and 90 min, respectively (Fig. 8) .
DISCUSSION
During inflammation, leukocytes, such as neutrophils and macrophages, provide a first line of defense against invading pathogens [3, 4, 7, 8] . However, excessive recruitment of neutrophils and macrophages into the tissues, including the lungs, may lead to bystander tissue damage and destruction of the architecture [26] . Therefore, regulation of neutrophil and macrophage infiltration into the tissues during inflammation could serve as an effective therapeutic tool to treat patients suffering from acute inflammation [7, 8, 27] . The focus of our previous study on MSP68 was to identify its therapeutic potential in sepsis by evaluating the status of neutrophil infiltration into the lung and other organs [20] . Despite playing a potential role in inhibiting neutrophil migration in remote organs during sepsis or under in vitro conditions, the final readouts of MSP68-mediated inhibition of neutrophil motility during inflammation remained to be barely observational unless its underlying mechanism is explored. Therefore, we have conducted the current study to define the mechanism of action by which MSP68 exerts its inhibitory effect on neutrophil adherence to extracellular matrix proteins, as well as endothelial cells, followed by their transmigration through the endothelial barrier that mimics their infiltration into the tissue beds. Our present study for identification of a novel mechanism by which MSP68 attenuated neutrophil and other immune cell migration after elucidation of its upstream binding receptors a 4 b 1 (VLA-4) and a M b 2 (Mac-1) integrins, followed by the modulation of the downstream signal transduction pathway related to cell migration, will improve our understanding of the mode of action of this novel, short peptide.
In response to the release of inflammatory mediators, including TNF-a, the vascular endothelium becomes activated, thus inducing profound changes in gene-expression profiles and functions that allow the endothelial cells to participate in various inflammatory processes [28] . Upon activation, the vascular endothelium secretes a range of cytokines, chemokines, and colony-stimulating factors, as well as up-regulates expression of adhesion molecules, such as ICAM-1 and VCAM-1, on the luminal surface [29] . In our study, we confirmed that gene expression of both ICAM-1 and VCAM-1 was up-regulated on activated PAECs. After activated neutrophils are captured and roll along microvascular walls with low-affinity interaction of selectins expressed on endothelial cells [30] , they create firm adhesion on endothelial cells by making bridges between integrins on neutrophils and ICAM-1/VCAM-1 on endothelial cells. Integrins a L b 2 (LFA-1) and a M b 2 (Mac-1) are important for neutrophils to bind to ICAM-1 on endothelial cells [31] . In addition, integrin a 4 b 1 (VLA-4) can be used by neutrophils for binding to VCAM-1 on endothelial cells [32] . In our study, we demonstrate that MSP68 inhibits neutrophil adhesion to activated PAECs, as well as to the VCAM-1, thus identifying a plausible mechanism by which MSP68-mediated inhibition of the neutrophil functions under inflamed conditions.
To define how MSP68 inhibited neutrophil adhesion to the cell adhesion molecules, we first focused on adhesion molecule receptors on neutrophils, as these receptors are required for the formation of bridges between these 2 cell populations. Our SPR approach clearly revealed MSP68 to recognize Mac-1 and VLA-4 directly on neutrophils. This has important implications, in that Mac-1 and VLA-4 act as the receptors for cell adhesion molecules on endothelial cells. As noticed from the K D obtained from SPR analysis, between these 2 integrins, MSP68 had lower affinity to Mac-1, which serves as the receptor for ICAM-1. Therefore, this might address the circumstances of reduced inhibitory effects of MSP68 on adhesion of the neutrophil to the ICAM-1 molecule, as shown in Fig. 2C . On the other hand, the considerably higher affinity of MSP68 to VLA-4, the receptor for VCAM-1, enabled it to inhibit more strongly neutrophil binding to the VCAM-1 (Fig. 2D) .
The adhesion of neutrophils to endothelial cells is also regulated by the expression levels of integrins [33, 34] . With the consideration of this fact, we have measured the mRNA levels of integrins b 1 and b 2 in BMDNs, with or without MSP68, by qRT-PCR. The results show no change in mRNA levels in BMDNs after treatment with MSP68 (data not shown). Moreover, we have also assessed the activation status of integrin b 1 on MSP68-treated BMDNs by flow cytometry using the antibody against the activation site of integrin b 1 and observed no change in the expression of activated integrin b 1 with MSP68 treatment (data not shown). These results further support that the inhibitory effect of MSP68 on neutrophil adhesion is a result of direct binding to integrins and interference with their interaction with VCAM-1.
MSP68 is a valine-RGD-valine peptide containing a single RGD motif. The RGD motif enables a particular ligand to bind to its respective integrin, thus regulating cell growth, migration, and survival [23] . Although MFG-E8 shows considerable homology among its amino acid sequences between human and mouse origins [35] , the sequence of MSP68 is found exclusively in the Figure 8 . MSP68 down-regulates the p-p38 in BMDN. BMDNs, stimulated by 10 nM fMLP, were incubated for indicated time periods in the presence or absence of 10 nM MSP68. The expression of p-p38 and total p38 was determined by Western blotting. Blots were scanned and quantified with densitometry. For the image, dashed lines indicate lanes from different membranes. Several gels were run to determine the effect of MSP68 on fMLP-induced p38 activation in BMDNs, while the band intensity of each p-p38 signal was normalized to its corresponding band intensities of total p38 and b-actin. The one without stimulation by both fMLP and MSP68 was designated as 1 for comparison. Representative blots are shown from 2 independent experiments. parent human MFG-E8 protein, not in mouse or any other species. In fact, several synthetic peptides containing the RGD sequence are shown to compete with adhesive molecules for binding to integrins and to disrupt the cellular activities mediated by integrin interaction. Moon et al. [36] demonstrated that a synthetic RGD-serine peptide attenuated LPS-induced pulmonary inflammation and reduced neutrophil infiltration into the lungs by inhibiting integrin-mediated MAPK activation. Fondevila et al. [37] has shown that the administration of cyclic RGD peptides inhibited the macrophage and neutrophil recruitment in steatotic liver cold ischemia-reperfusion injury. Recently, our group has also demonstrated cyclic RGD peptides to lower neutrophil infiltration in ALI after an intestinal ischemia-reperfusion model in mice [38] . This evidence strengthens our findings of MSP68 as a novel neutrophil infiltration regulator, although the differences of characteristic features between MSP68 and other synthetic RGD peptides remain to be explored in future studies.
Following initial adhesive events, neutrophils crawl along the surface of endothelial cells and then transmigrate from the vascular lumen by passing between (paracellular) or through (transcellular) endothelial cells into inflamed tissues [39] . In addition to its inhibitory effect of neutrophil adhesion, we revealed that MSP68 attenuated neutrophil transmigration as well as migration toward chemoattractants C5a, fMLP, and MIP-2. To migrate toward diverse chemoattractants, neutrophils express various surfaces receptors, including FPR, C5aR, leukotriene B 4 receptor, CXCR1 and CXCR2, and CCR1 and CCR2 [40, 41] . These receptors belong to a family of GPCRs, characterized by 7 transmembrane domains and coupled with heterotrimeric G proteins [42, 43] . Engagement of GPCRs activates 2 parallel pathways. One of the signals triggered by GPCRs in neutrophils is a prominent biphasic Ca 2+ signal.
Another pathway is the activation of PI3K to generate phosphatidylinositol (3,4,5)-trisphosphate lipid moieties as a signal messenger and to induce other kinases, including p38 MAPK [44] . Prior pharmacological studies suggested a positive role for the p38 MAPK pathway in GPCR signaling in neutrophils, and a recent study also revealed that p38 MAPK promotes neutrophil migration by interfering with GPCR kinase 2-mediated desensitization of FPRs [45] [46] [47] . As the MAPK p38 pathway is central to a wide range of downstream signaling cascades for neutrophil migration [48, 49] , in our present study, therefore, we assessed the activation status of pp38 in fMLP-activated neutrophils, which showed that p38 activation was highly up-regulated after the stimulation of neutrophils by fMLP. On the other hand, MSP68 treatment decreased the activation of p38. This result implies that MSP68 attenuates neutrophil migration by down-regulating the p38 signaling pathway. Aside from this, in a recent study, we have identified that MSP68 modulates neutrophil cytoskeletal arrangement by down-regulating fMLP-induced, small GTPase Rac1 activation [50] . Therefore, we summarize that MSP68 can attenuate neutrophil migration by inhibiting MAPKs, as well as small GTPase Rac1 activation. Of note, gene-expression levels of C5aR, FPR, and CXCR2, in activated BMDNs after treatment with MSP68, were not affected by MSP68 treatment (data not shown).
In the current study, we have identified the putative receptors of MSP68 binding to integrins a M b 2 and a 4 b 1 . This suggested that by binding to these integrins, MSP68 could down-regulate intracellular signaling pathways that are involved in neutrophil migration. Our current study demonstrated MSP68 to inhibit neutrophil migration by down-regulating intracellular signal transduction, which might indirectly attenuate inflammation and further protect tissues from injury during sepsis, whereas a direct anti-inflammatory function of MSP68, by binding to these integrins expressed on macrophages, monocytes, and T cells to cause immune dysfunction, remains undefined. Further study to reveal the direct anti-inflammatory role of MSP68 on these cells could be of interest. To delineate the mechanism of action of MSP68, our current, as well as previous, studies have identified that MSP68 was able to down-modulate neutrophil migration through binding to its putative integrins and by modulating downstream MAPK and small GTPase Rac1-mediated signal transductions [50] that are usually known for promoting neutrophil migration.
Other than neutrophils, to know the role of MSP68 in macrophages and T cells, in this study, we have demonstrated that human macrophage-like THP-1 cells had significant inhibition in their adherence to endothelial cells at a higher concentration of MSP68 (50 nM) treatment, whereas no effect of MSP68 on the human T cell adhesion to endothelial cells was observed (data not shown). This observation led us to assess further the status of the MSP68 receptor, integrin, expression on these cells, which revealed that the expression of 1 of the putative integrins a 4 was significantly higher in both THP-1 and Jurkat cells compared with the primary BMDNs, whereas the expression of the a 4 integrin in Jurkat cells was even found to be significantly higher than that of THP-1 cells. As a result, these higher levels of a 4 integrin expression in THP-1 and Jurkat cells, with the doses of MSP68 that were used for the inhibition of neutrophil migration, might not be sufficient for these cells to inhibit their adhesion to the endothelial cells or to modulate their signal transduction. Hence, the degree of MSP68-mediated inhibition of neutrophils, macrophages, and T cells infiltrating to the organs is varied.
In conclusion, we have demonstrated that the mechanism of MSP68-mediated inhibition of neutrophil and macrophage infiltration into the lungs is via attenuation of the interaction between cell adhesion molecules on endothelial cells and their putative ligands on neutrophils and macrophages. We have also identified that inhibition of p38 MAPK activation by MSP68 may play a role in regulating immune cell migration. Thus, MSP68 is a potential candidate to be developed as a novel, therapeutic agent for treating inflammatory diseases caused by immune cell infiltration. 
